Physician profile
Robert Barwick
NPI 1063878064
$586.35
in general payments reported to CMS, 2019-2025
14 companies · $16.38 in 2025
The $16.38 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.42 · 2022: $202 · 2023: $156 · 2024: $196 · 2025: $16.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $367.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $115.52 | 2023-2025 | |
| Abbvie INC. | $86.76 | 2022-2023 | |
| Exact Sciences Corporation | $77.98 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $67.58 | 2021-2024 | |
| Amgen INC. | $55.49 | 2022-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.77 | 2022-2023 | Jardiance |
| Idorsia Pharmaceuticals US INC | $22.86 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $22.07 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $19.69 | 2022 | |
| Medtronic, INC. | $17.93 | 2024 | Intellis Adaptivestim |
| Bayer Healthcare Pharmaceuticals INC. | $16.96 | 2022 | |
| Tris Pharma INC | $16.27 | 2023 | Dyanavel Xr |
| Lilly USA, LLC | $14.53 | 2023 | Mounjaro |
| Biohaven Pharmaceutical Holding Company Ltd. | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Barwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.